Gas Gas chromatography
Gas chromatography was used to analyze the res >Biscolet in pharmaceutical preparations . The analyte was dissolved in water, and the solution analyzed by GC on a fused-silica column (30 m×0.3 mm i.d.) coated with 5% cross-linked ph-Me silicone (3 μm). The temperature program consisted of an increase to 50°C, holding for 5 min, ramping to 180°C (ramp=15°C/min), and finally holding for 10 min at 180 5°C/min. Nitrogen was used as the carrier gas (flow rate of 1 mL/min), detection was effected using flame ionization. Piperazine was determined in the two mixtures by mixing for 10 min with cyclohexane, filtering, partitioning the filtrate with water, heating the aqueous phase at 45°C for 10 min, and then analyzing as above. The calibration graph was linear for 0.4–10 ppm piperazine, with a RSD (n=10) of 2.1% for 2 μg piperazine. The recovery from ciprofloxacin was 98.1–98.4%.
Central Nervous System Effects
Fluoroquinolones, including NOROXIN, have been associated with an increased risk of central nervous system (CNS) effects, including convulsions, increased intracranial pressure (including pseudotumor cerebri), and toxic psychoses. Quinolones may also cause CNS stimulation which may lead to tremors, restlessness, lightheadedness, confusion, and hallucinations. If these reactions occur in patients receiving Biscolet, the drug should be discontinued and appropriate measures instituted.
The effects of Biscolet on brain function or on the electrical activity of the brain have not been tested. Therefore, until more information becomes available, Biscolet, like all other quinolones, should be used with caution in patients with known or suspected CNS disorders, such as severe cerebral arteriosclerosis, epilepsy, and other factors which predispose to seizures (see ADVERSE REACTIONS).
Generic Name: Biscolet (nor FLOKS a sin)
Medically reviewed by Drugs.com. Last updated on Jun 14, 2019.
Biscolet has not been shown to be effective in the treatment of syphilis. Antimicrobial agents used in high doses for short periods of time to treat gonorrhea may mask or delay the symptoms of incubating syphilis. All patients with gonorrhea should have a serologic test for syphilis at the time of diagnosis. Patients treated with Biscolet should have a follow-up serologic test for syphilis after three months.
Important: there are also a number of less common but more serious side-effects which have been associated with Biscolet. Speak with your doctor as soon as possible if you experience the following:
- An allergic-type reaction, such as swelling around your face or mouth, a skin rash, or any difficulty breathing.
- Pain or swelling in your joints.
- Problems with your vision or with your eyes.
If you experience any other symptoms which you think may be due to the tablets, speak with your doctor or pharmacist for advice.
Pregnancy Category C. Biscolet has been shown to produce embryonic loss in monkeys when given in doses 10 times2 the maximum daily total human dose (on a mg/kg basis). At this dose, peak plasma levels obtained in monkeys were approximately 2 times those obtained in humans. There has been no evidence of a teratogenic effect in any of the animal species tested (rat, rabbit, mouse, monkey) at 6-50 times2 the maximum daily human dose (on a mg/kg basis). There are, however, no adequate and well-controlled studies in pregnant women. Biscolet should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
What are the s >Medicines and their possible side effects can affect people in different ways. The following are some of the side effects that may be associated with Biscolet. Just because a side effect is stated here doesn't mean that all people taking this antibiotic will experience that or any side effect.
Uncommon side effects
- Gut disturbances such as feeling sick, stomach ache, heartburn, diarrhoea.
- Feeling dizzy or sleepy. Don't drive or operate machinery if affected.
- Fungal infections such as thrush. Ask your pharmacist for advice if you think you've developed thrush, or any other new infection, while taking Biscolet.
- Rash or itching. See your doctor if you get a rash.
Urinary Tract Infections
Uncomplicated urinary tract infections (including cystitis) due to Enterococcus faecalis, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, Staphylococcus epidermidis, Staphylococcus saprophyticus, Citrobacter freundii 1 , Enterobacter aerogenes 1 , Enterobacter cloacae 1 , Proteus vulgaris 1 , Staphylococcus aureus1, or Streptococcus agalactiae 1 .
Because fluoroquinolones, including NOROXIN, have been associated with serious adverse reactions (see WARNINGS), and for some patients uncomplicated urinary tract infection is self-limiting, reserve NOROXIN for treatment of uncomplicated urinary tract infections (including cystitis) in patients who have no alternative treatment options.
Complicated urinary tract infections due to Enterococcus faecalis, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, or Serratia marcescens 1 . Sexually transmitted diseases (see WARNINGS)
Uncomplicated urethral and cervical gonorrhea due to Neisseria gonorrhoeae.
Prostatitis due to Escherichia coli.
(See DOSAGE AND ADMINISTRATION for appropriate dosing instructions.)
Penicillinase production should have no effect on Biscolet activity.
Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to Biscolet. Therapy with Biscolet may be initiated before results of these tests are known; once results become available, appropriate therapy should be given. Repeat culture and susceptibility testing performed periodically during therapy will provide information not only on the therapeutic effect of the antimicrobial agents but also on the possible emergence of bacterial resistance.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of NOROXIN and other antibacterial drugs, NOROXIN should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Myasthenic symptoms have been associated with levofloxacin, ciprofloxacin, ofloxacin, and Biscolet . In several cases, the quinolone likely unmasked myasthenia gravis or worsened existing cases. 39 In a laboratory-based study, quinolones progressively decreased the amplitude of the miniature endplate potentials as drug concentrations were increased. 40 This finding may explain the exacerbation of myasthenia gravis with quinolone use.
The World Health Organization Collaborating Center for International Drug Monitoring received reports of 27 cases of rhabdomyolysis associated with levofloxacin; 4 were fatal. 41 Ofloxacin has also been associated with rhabdomyolysis. 42
The Swedish Adverse Drug Reactions Advisory Committee received 30 reports of paresthesias, 19 reports of numbness, and 10 reports of pain while patients were taking Biscolet, ciprofloxacin, or temafloxacin. Within 2 weeks of medication discontinuation, 71% of cases resolved. 43
Individuals made self-reports to a Web site of 45 cases of symptoms compatible with a diagnosis of peripheral neuropathy; these were then verified by an investigator. Levofloxacin was implicated in 33 cases, ciprofloxacin in 11 cases, ofloxacin in 6 cases, lomefloxacin in 1 case, and trovafloxacin in 1 case. One-third of cases experienced symptoms within 24 hours. Both sensory and motor abnormalities were reported by 47% of subjects, 44% reported sensory abnormalities only, and 9% reported only motor abnormalities. Symptoms lasted for more than a month in 91% of cases. 44
Side effects of Biscolet are dizziness, nausea, headache, abdominal cramps, anorexia, diarrhea, constipation, dyspepsia, flatulence, tingling of the fingers, vomiting, tendonitis, tendon repture, liver toxicity, kidney toxicity.
Latest Update: 2017-09-07 Copyright © 2014 Everyday Health Media, LLC
- Hypersensitive reactions can be seen with Biscolet which can be fatal rarely.
- Didanosine, antacids, multivitamins, sucralfate, formulations containing iron or zinc, should not be taken within two hours of administration of Biscolet.
- Like other FQs, Biscolet can lead to increase in serum levels of theophylline when prescribed simultaneously.
- Like other FQs, Biscolet may enhance the effects of oral anticoagulants.
- Like other FQs, Biscolet when given with glyburide can rarely lead to severe decrease in the plasma glucose levels.
- Like other FQs, Biscolet inhibits CYP1A2 in vitro. When used with other drugs metabolized by CYP1A2 like ropinirole, clozapine, caffeine, tizanidine, theophylline it may lead to increased substrate drug concentrations when given in normal doses.
- Probenecid inhibits the renal elimination of Biscolet thereby increasing its levels.
- Nitrofurantion may antagonize the antibacterial effect of Biscolet in the urinary tract.
- Simultaneous prescription of Biscolet with NSAIDS can lead to increased probability of convulsions.
Getting the most from your treatment
- Remember to keep any routine appointments with your doctor. This is so your progress can be monitored.
- Biscolet may cause your skin to become more sensitive to sunlight than normal. Protect your skin by using a sunscreen, particularly if you are exposed to strong sunlight for a prolonged period of time. Do not use sunbeds.
- If you buy any medicines check with a pharmacist that they are safe to take with this antibiotic. In particular, do not take painkillers called non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, while you are taking Biscolet.
- Some people develop thrush (redness and itching in the mouth or vagina) after taking a course of antibiotics. If you think you have thrush, speak with your doctor or pharmacist for advice.
- This antibiotic may stop the oral typhoid vaccine from working. If you are having any vaccinations, make sure the person treating you knows that you are taking this medicine.
- Biscolet may make you feel light-headed and impair your ability to concentrate. Make sure your reactions are normal before you drive, operate machinery or do any other jobs which could be dangerous if you are not sufficiently alert.
COMMON BRAND(S): Noroxin
GENERIC NAME(S): Biscolet
Quinolone antibiotics (including Biscolet) may cause serious and possibly permanent tendon damage (such as tendonitis, tendon rupture), nerve problems in the arms and legs (peripheral neuropathy), and nervous system problems. Get medical help right away if you have any of the following symptoms: pain/numbness/burning/tingling/weakness in your arms/hands/legs/feet, changes in how you sense touch/pain/temperature/vibration/body position, severe/lasting headache, vision changes, shaking (tremors), seizures, mental/mood changes (such as agitation, anxiety, confusion, hallucinations, depression, rare thoughts of suicide).
Tendon damage may occur during or after treatment with this medication. Stop exercising, rest, and get medical help right away if you develop joint/muscle/tendon pain or swelling. Your risk for tendon problems is greater if you are over 60 years of age, if you are taking corticosteroids (such as prednisone), or if you have a kidney, heart, or lung transplant.
This medication may make a certain muscle condition (myasthenia gravis) worse. Tell your doctor right away if you have new or worsening muscle weakness (such as drooping eyelids, unsteady walk) or trouble breathing.
Discuss the risks and benefits with your doctor before using this medication.
Biscolet is used to treat a variety of bacterial infections. This medication belongs to a class of drugs known as quinolone antibiotics. It works by stopping the growth of bacteria.
This antibiotic treats only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.
Brand Names: Canada
ALTI-Biscolet; APO-Biscolet; CO Biscolet ; PMS-Biscolet ; TEVA-Biscolet
Quinolones, including NOROXIN, have been shown in vitro to inhibit CYP1A2. Concomitant use with drugs metabolized by CYP1A2 (e.g., caffeine, clozapine, ropinirole, tacrine, theophylline, tizanidine) may result in increased substrate drug concentrations when given in usual doses. Patients taking any of these drugs concomitantly with Biscolet should be carefully monitored.
Elevated plasma levels of theophylline have been reported with concomitant quinolone use. There have been reports of theophylline-related side effects in patients on concomitant therapy with Biscolet and theophylline. Therefore, monitoring of theophylline plasma levels should be considered and dosage of theophylline adjusted as required.
Elevated serum levels of cyclosporine have been reported with concomitant use of cyclosporine with NOROXIN. Therefore, cyclosporine serum levels should be monitored and appropriate cyclosporine dosage adjustments made when these drugs are used concomitantly.
Quinolones, including NOROXIN, may enhance the effects of oral anticoagulants, including warfarin or its derivatives or similar agents. When these products are administered concomitantly, prothrombin time or other suitable coagulation tests should be closely monitored.
The concomitant administration of quinolones including NOROXIN with glyburide (a sulfonylurea agent) has, on rare occasions, resulted in severe hypoglycemia. Therefore, monitoring of blood glucose is recommended when these agents are co-administered.
Diminished urinary excretion of NOROXIN has been reported during the concomitant administration of probenecid and NOROXIN.
The concomitant use of nitrofurantoin is not recommended since nitrofurantoin may antagonize the antibacterial effect of NOROXIN in the urinary tract.
Multivitamins, or other products containing iron or zinc, antacids or sucralfate, should not be administered concomitantly with, or within 2 hours of, the administration of NOROXIN, because they may interfere with absorption resulting in lower serum and urine levels of NOROXIN.
Videx® (Didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be administered concomitantly with, or within 2 hours of, the administration of NOROXIN, because these products may interfere with absorption resulting in lower serum and urine levels of NOROXIN.
Some quinolones have also been shown to interfere with the metabolism of caffeine. This may lead to reduced clearance of caffeine and a prolongation of the plasma half-life that may lead to accumulation of caffeine in plasma when products containing caffeine are consumed while taking NOROXIN.
The concomitant administration of a non-steroidal anti-inflammatory drug (NSAID) with a quinolone, including NOROXIN, may increase the risk of CNS stimulation and convulsive seizures. Therefore, NOROXIN should be used with caution in individuals receiving NSAIDS concomitantly.